Compare Star Bulk Carriers Corp (SBLK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Star Bulk Carriers Corp trades at $29.06 (market cap $3.46B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Star Bulk Carriers Corp pays a 6.31% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 23 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SBLK | TVTX | |
|---|---|---|
Market Cap | $3.46B | $4.88B |
Volume | 1,078,337 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $32.49 | $67.52 |
52-Week Low | $17.42 | $26.79 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $4.14B | $5.01B |
Dividend Yield | 6.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $29.79, down 0.17% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 23.87% net income margin and has beaten earnings estimates for three consecutive quarters. Recent insider buying activity and a 58.34% analyst buy rating signal confidence, while the stock offers an attractive valuation with P/E of 11.68 and upcoming $0.90 dividend payment.
SBLK presents a compelling value opportunity with strong earnings momentum and shareholder returns, though technical weakness and shipping sector volatility pose near-term risks. The company's 100% free cash flow distribution policy and projected revenue growth to $1.2B in 2026 support the bullish fundamental case, while bearish moving averages suggest potential consolidation before further upside.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
